Press release

Siemens Healthineers Intends to Close Fast Track Diagnostics

Published on March 18, 2024
  • Shift follows a periodic strategic review of portfolio contributions and market opportunity 
  • Demand for Fast Track Diagnostic testing portfolio declined significantly from peak of pandemic 
  • Diagnostics business to focus on centralized laboratory testing, specialty testing, point of care

Siemens Healthineers announced today it intends to close its Fast Track Diagnostics unit, a small collection of polymerase chain reaction (PCR) testing products that is part of the Diagnostics business. This portfolio is primarily sold in Europe. Demand for the Fast Track Diagnostics portfolio has fallen significantly since the peak of the COVID-19 pandemic. Fast Track Diagnostics is a minor player in the molecular diagnostics space and represents a very small part of the overall revenue of the Siemens Healthineers Diagnostics business. 

About 90 employees, mostly based in Luxembourg, are affected. Conversations with local employee representatives are under way, and local labor regulations and guidelines will be followed in accordance with standard company practice. Siemens Healthineers intends to close the Fast Track Diagnostics unit by September 2024. 

Siemens Healthineers offers in vitro diagnostic test solutions for nearly every clinical environment. Its central laboratory analyzers are used in research laboratories, clinical laboratories of local community hospitals, independent specialty laboratories, and in the largest reference labs in the world. Point-of-care testing solutions support care everywhere from remote pop-up health clinics to community physician offices, and outpatient care facilities to patients’ bedsides in hospital units. Siemens Healthineers has differentiated its in vitro diagnostic test offerings with flexible, scalable, and integrated automation capabilities that increase control over laboratory testing and operational workflows.

Siemens Healthineers 2024

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2023, which ended on September 30, 2023, Siemens Healthineers had approximately 71,000 employees worldwide and generated revenue of around €21.7 billion. Further information is available at